CN Patent

CN108299394A — 来那替尼二马来酸盐晶型及其制备方法

Assigned to An Rite (shanghai) Pharmaceutical Technology Co Ltd · Expires 2018-07-20 · 8y expired

What this patent protects

本发明涉及来那替尼二马来酸盐晶型及其制备方法。具体地，本发明公开了来那替尼二马来酸盐的三种晶型，分别为晶型IV、V、VI，均为来那替尼二马来酸盐的无水物，其中，晶型IV和V具有比已知的晶型II具有更好的溶解性，晶型V具有更低的吸湿性，相对湿度变化不会引起晶型的转变。本发明还公开了上述三种晶型适宜药物研究及工业化生产的制备方法。

USPTO Abstract

本发明涉及来那替尼二马来酸盐晶型及其制备方法。具体地，本发明公开了来那替尼二马来酸盐的三种晶型，分别为晶型IV、V、VI，均为来那替尼二马来酸盐的无水物，其中，晶型IV和V具有比已知的晶型II具有更好的溶解性，晶型V具有更低的吸湿性，相对湿度变化不会引起晶型的转变。本发明还公开了上述三种晶型适宜药物研究及工业化生产的制备方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN108299394A
Jurisdiction
CN
Classification
—
Expires
2018-07-20
Drug substance claim
No
Drug product claim
No
Assignee
An Rite (shanghai) Pharmaceutical Technology Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.